When David Weiskopf joined Chiron in March 2005, the biotech company was in a crisis.
Six months earlier, it had announced the grim news that production problems at a UK facility in Liverpool had left officials unable to provide roughly half of the US flu vaccine supplies.
"[My role] was essentially to come in and build a first-class communications team, work with senior management on the Fluvirin flu vaccine challenge, and to develop a strategy to relaunch our corporate brand image," says ...